Evidence map›Paper›PMID 38245603›Full record

ArticleScientific reports2024

Development and validation of cost-effective SYBR Green-based RT-qPCR and its evaluation in a sample pooling strategy for detecting SARS-CoV-2 infection in the Indonesian setting.

Ratika Rahmasari, Muhareva Raekiansyah, Siti Hana Aliyah, Priska Yodi, Fathan Baihaqy, Muhamad Irhamsyah, Kartika Citra Dewi Permata Sari, Herman Suryadi, Meng Ling Moi, Rani Sauriasari

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Foods (Basel, Switzerland) · 2026
    Article
  2. Article
  3. Chloroplast DNA markers for distinguishing seaweedsFood science and biotechnology · 2025
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Ratika Rahmasari *Microbiology and Biotechnology Laboratory, Faculty of Pharmacy, Universitas Indonesia, Depok, West Java, Indonesia. ratika.rahmasari@farmasi.ui.ac.id.
Muhareva Raekiansyah *Helix Laboratory & Clinic, Depok, West Java, Indonesia.
Siti Hana AliyahMicrobiology and Biotechnology Laboratory, Faculty of Pharmacy, Universitas Indonesia, Depok, West Java, Indonesia.
Priska YodiMicrobiology and Biotechnology Laboratory, Faculty of Pharmacy, Universitas Indonesia, Depok, West Java, Indonesia.
Fathan BaihaqyHelix Laboratory & Clinic, Depok, West Java, Indonesia.
Muhamad IrhamsyahHelix Laboratory & Clinic, Depok, West Java, Indonesia.
Kartika Citra Dewi Permata SariClinical Pharmacy and Social Pharmacy Laboratory, Faculty of Pharmacy, Universitas Indonesia, Depok, West Java, Indonesia.
Herman SuryadiMicrobiology and Biotechnology Laboratory, Faculty of Pharmacy, Universitas Indonesia, Depok, West Java, Indonesia.
Meng Ling MoiSchool of International Health, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Rani SauriasariClinical Pharmacy and Social Pharmacy Laboratory, Faculty of Pharmacy, Universitas Indonesia, Depok, West Java, Indonesia.
University of Indonesia · IDBandung Institute of Technology · IDThe University of Tokyo · JP

Funding

Universitas Indonesia PUTI Q2 grant No. SKU-147/UN2. R3/HKP.05/2022.
6 · The paper itself

Abstract

A low-cost SYBR Green-based RT-qPCR method to detect SARS-CoV-2 were developed and validated. Primers targeting a conserved and vital region of the N genes of SARS-CoV-2 were designed. In-silico study was performed to analyse the compatibility of the selected primer pair with Indonesian SARS-CoV-2 genome sequences available from the GISAID database. We determined the linearity of our new assay using serial dilution of SARS-CoV-2 RNA from clinical samples with known virus concentration. The assay was then evaluated using clinically relevant samples in comparison to a commercial TaqMan-based test kit. Finally, we applied the assay in sample pooling strategies for SARS-CoV-2 detection. The SYBR Green-based RT-qPCR method was successfully developed with sufficient sensitivity. There is a very low prevalence of genome variation in the selected N primer binding regions, indicating their high conservation. The validation of the assay using clinical samples demonstrated similar performance to the TaqMan method suggesting the SYBR methods is reliable. The pooling strategy by combining 5 RNA samples for SARS-CoV-2 detection using the SYBR RT-qPCR methods is feasible and provides a high diagnostic yield. However, when dealing with samples having a very low viral load, it may increase the risk of missing positive cases.

Indexed as

BenzothiazolesCOVID-19DiaminesQuinolinesCost-Benefit AnalysisHumansIndonesiaRNA, ViralSARS-CoV-2Sensitivity and SpecificityBenzothiazolesDiaminesQuinolinesRNA, ViralSYBR Green I

Identifiers

PMID38245603
PMCPMC10799953
OpenAlexW4391048176

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.